The drug giants Merck and Sanofi each said they would acquire a smaller drug maker for more than $2 billion Monday — in each case, more than double the smaller company’s market capitalization — cheering investors about large companies’ appetite to execute buyouts in the biotechnology sector.

Merck, of Kenilworth, N.J., is purchasing ArQule of Burlington, Mass., a developer of pills aimed at treating multiple cancers, for $2.7 billion, or $20 per share, a 107% premium to the stock’s closing price Friday. Sanofi, based in Paris, will buy Synthorx, a San Diego firm using a synthetic DNA base pair to create new drugs for cancer and autoimmune disease, for $2.5 billion, or $68 per share, a 172% premium to Synthorx’s stock price Friday.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Giving away the store is OK with these companies but is someone keeping track of how the monies are being spent. Is “RETURN on INVESTMENT ?” ever in company’s thought process. If the companies are paying for knowledge base that suggests that companies have wrong focus.

    No matter what transpires one thing is sure that drugs are going to unaffordable even to the folks who have piles of monies. Overall healthcare cost is going to go up and “C” suit is going to get ugly fat and rich. Sorry “C” suit! this is based on your track record.

Your daily dose of news in health and medicine

Privacy Policy